

Global Oncology Biosimilars Market Growth (Status and Outlook) 2023-2029

<https://marketpublishers.com/r/GA935E0DE7C5EN.html>

Date: February 2023

Pages: 101

Price: US\$ 3,660.00 (Single User License)

ID: GA935E0DE7C5EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.

LPI (LP Information)' newest research report, the "Oncology Biosimilars Industry Forecast" looks at past sales and reviews total world Oncology Biosimilars sales in 2022, providing a comprehensive analysis by region and market sector of projected Oncology Biosimilars sales for 2023 through 2029. With Oncology Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Oncology Biosimilars industry.

This Insight Report provides a comprehensive analysis of the global Oncology Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oncology Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position

in an accelerating global Oncology Biosimilars market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oncology Biosimilars and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oncology Biosimilars.

The global Oncology Biosimilars market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Oncology Biosimilars is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Oncology Biosimilars is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Oncology Biosimilars is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Oncology Biosimilars players cover Celltrion, Biocon, Dr. Reddy's Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd and Apotex, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Oncology Biosimilars market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Monoclonal Antibody

Hematopoietic Agents

G-CSF

Others

Segmentation by application

Retail Pharmacies

Hospital Pharmacy

Online Pharmacy

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Celltrion

Biocon

Dr. Reddy's Laboratories

STADA Arzneimittel AG

Intas Pharmaceuticals

Pfizer

Sandoz International

Teva Pharmaceutical Industries Ltd

Apotex

BIOCAD

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Oncology Biosimilars Market Size 2018-2029
 - 2.1.2 Oncology Biosimilars Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 Oncology Biosimilars Segment by Type
 - 2.2.1 Monoclonal Antibody
 - 2.2.2 Hematopoietic Agents
 - 2.2.3 G-CSF
 - 2.2.4 Others
- 2.3 Oncology Biosimilars Market Size by Type
 - 2.3.1 Oncology Biosimilars Market Size CAGR by Type (2018 VS 2022 VS 2029)
 - 2.3.2 Global Oncology Biosimilars Market Size Market Share by Type (2018-2023)
- 2.4 Oncology Biosimilars Segment by Application
 - 2.4.1 Retail Pharmacies
 - 2.4.2 Hospital Pharmacy
 - 2.4.3 Online Pharmacy
- 2.5 Oncology Biosimilars Market Size by Application
 - 2.5.1 Oncology Biosimilars Market Size CAGR by Application (2018 VS 2022 VS 2029)
 - 2.5.2 Global Oncology Biosimilars Market Size Market Share by Application (2018-2023)

3 ONCOLOGY BIOSIMILARS MARKET SIZE BY PLAYER

- 3.1 Oncology Biosimilars Market Size Market Share by Players

- 3.1.1 Global Oncology Biosimilars Revenue by Players (2018-2023)
- 3.1.2 Global Oncology Biosimilars Revenue Market Share by Players (2018-2023)
- 3.2 Global Oncology Biosimilars Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
 - 3.3.1 Competition Landscape Analysis
 - 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion

4 ONCOLOGY BIOSIMILARS BY REGIONS

- 4.1 Oncology Biosimilars Market Size by Regions (2018-2023)
- 4.2 Americas Oncology Biosimilars Market Size Growth (2018-2023)
- 4.3 APAC Oncology Biosimilars Market Size Growth (2018-2023)
- 4.4 Europe Oncology Biosimilars Market Size Growth (2018-2023)
- 4.5 Middle East & Africa Oncology Biosimilars Market Size Growth (2018-2023)

5 AMERICAS

- 5.1 Americas Oncology Biosimilars Market Size by Country (2018-2023)
- 5.2 Americas Oncology Biosimilars Market Size by Type (2018-2023)
- 5.3 Americas Oncology Biosimilars Market Size by Application (2018-2023)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Oncology Biosimilars Market Size by Region (2018-2023)
- 6.2 APAC Oncology Biosimilars Market Size by Type (2018-2023)
- 6.3 APAC Oncology Biosimilars Market Size by Application (2018-2023)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe Oncology Biosimilars by Country (2018-2023)
- 7.2 Europe Oncology Biosimilars Market Size by Type (2018-2023)
- 7.3 Europe Oncology Biosimilars Market Size by Application (2018-2023)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Oncology Biosimilars by Region (2018-2023)
- 8.2 Middle East & Africa Oncology Biosimilars Market Size by Type (2018-2023)
- 8.3 Middle East & Africa Oncology Biosimilars Market Size by Application (2018-2023)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL ONCOLOGY BIOSIMILARS MARKET FORECAST

- 10.1 Global Oncology Biosimilars Forecast by Regions (2024-2029)
 - 10.1.1 Global Oncology Biosimilars Forecast by Regions (2024-2029)
 - 10.1.2 Americas Oncology Biosimilars Forecast
 - 10.1.3 APAC Oncology Biosimilars Forecast
 - 10.1.4 Europe Oncology Biosimilars Forecast
 - 10.1.5 Middle East & Africa Oncology Biosimilars Forecast
- 10.2 Americas Oncology Biosimilars Forecast by Country (2024-2029)
 - 10.2.1 United States Oncology Biosimilars Market Forecast
 - 10.2.2 Canada Oncology Biosimilars Market Forecast

- 10.2.3 Mexico Oncology Biosimilars Market Forecast
- 10.2.4 Brazil Oncology Biosimilars Market Forecast
- 10.3 APAC Oncology Biosimilars Forecast by Region (2024-2029)
 - 10.3.1 China Oncology Biosimilars Market Forecast
 - 10.3.2 Japan Oncology Biosimilars Market Forecast
 - 10.3.3 Korea Oncology Biosimilars Market Forecast
 - 10.3.4 Southeast Asia Oncology Biosimilars Market Forecast
 - 10.3.5 India Oncology Biosimilars Market Forecast
 - 10.3.6 Australia Oncology Biosimilars Market Forecast
- 10.4 Europe Oncology Biosimilars Forecast by Country (2024-2029)
 - 10.4.1 Germany Oncology Biosimilars Market Forecast
 - 10.4.2 France Oncology Biosimilars Market Forecast
 - 10.4.3 UK Oncology Biosimilars Market Forecast
 - 10.4.4 Italy Oncology Biosimilars Market Forecast
 - 10.4.5 Russia Oncology Biosimilars Market Forecast
- 10.5 Middle East & Africa Oncology Biosimilars Forecast by Region (2024-2029)
 - 10.5.1 Egypt Oncology Biosimilars Market Forecast
 - 10.5.2 South Africa Oncology Biosimilars Market Forecast
 - 10.5.3 Israel Oncology Biosimilars Market Forecast
 - 10.5.4 Turkey Oncology Biosimilars Market Forecast
 - 10.5.5 GCC Countries Oncology Biosimilars Market Forecast
- 10.6 Global Oncology Biosimilars Forecast by Type (2024-2029)
- 10.7 Global Oncology Biosimilars Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

11.1 Celltrion

- 11.1.1 Celltrion Company Information
- 11.1.2 Celltrion Oncology Biosimilars Product Offered
- 11.1.3 Celltrion Oncology Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
- 11.1.4 Celltrion Main Business Overview
- 11.1.5 Celltrion Latest Developments

11.2 Biocon

- 11.2.1 Biocon Company Information
- 11.2.2 Biocon Oncology Biosimilars Product Offered
- 11.2.3 Biocon Oncology Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
- 11.2.4 Biocon Main Business Overview

- 11.2.5 Biocon Latest Developments
- 11.3 Dr. Reddy's Laboratories
 - 11.3.1 Dr. Reddy's Laboratories Company Information
 - 11.3.2 Dr. Reddy's Laboratories Oncology Biosimilars Product Offered
 - 11.3.3 Dr. Reddy's Laboratories Oncology Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
 - 11.3.4 Dr. Reddy's Laboratories Main Business Overview
 - 11.3.5 Dr. Reddy's Laboratories Latest Developments
- 11.4 STADA Arzneimittel AG
 - 11.4.1 STADA Arzneimittel AG Company Information
 - 11.4.2 STADA Arzneimittel AG Oncology Biosimilars Product Offered
 - 11.4.3 STADA Arzneimittel AG Oncology Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
 - 11.4.4 STADA Arzneimittel AG Main Business Overview
 - 11.4.5 STADA Arzneimittel AG Latest Developments
- 11.5 Intas Pharmaceuticals
 - 11.5.1 Intas Pharmaceuticals Company Information
 - 11.5.2 Intas Pharmaceuticals Oncology Biosimilars Product Offered
 - 11.5.3 Intas Pharmaceuticals Oncology Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
 - 11.5.4 Intas Pharmaceuticals Main Business Overview
 - 11.5.5 Intas Pharmaceuticals Latest Developments
- 11.6 Pfizer
 - 11.6.1 Pfizer Company Information
 - 11.6.2 Pfizer Oncology Biosimilars Product Offered
 - 11.6.3 Pfizer Oncology Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
 - 11.6.4 Pfizer Main Business Overview
 - 11.6.5 Pfizer Latest Developments
- 11.7 Sandoz International
 - 11.7.1 Sandoz International Company Information
 - 11.7.2 Sandoz International Oncology Biosimilars Product Offered
 - 11.7.3 Sandoz International Oncology Biosimilars Revenue, Gross Margin and Market Share (2018-2023)
 - 11.7.4 Sandoz International Main Business Overview
 - 11.7.5 Sandoz International Latest Developments
- 11.8 Teva Pharmaceutical Industries Ltd
 - 11.8.1 Teva Pharmaceutical Industries Ltd Company Information
 - 11.8.2 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Offered

11.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue, Gross Margin and Market Share (2018-2023)

11.8.4 Teva Pharmaceutical Industries Ltd Main Business Overview

11.8.5 Teva Pharmaceutical Industries Ltd Latest Developments

11.9 Apotex

11.9.1 Apotex Company Information

11.9.2 Apotex Oncology Biosimilars Product Offered

11.9.3 Apotex Oncology Biosimilars Revenue, Gross Margin and Market Share (2018-2023)

11.9.4 Apotex Main Business Overview

11.9.5 Apotex Latest Developments

11.10 BIOCAD

11.10.1 BIOCAD Company Information

11.10.2 BIOCAD Oncology Biosimilars Product Offered

11.10.3 BIOCAD Oncology Biosimilars Revenue, Gross Margin and Market Share (2018-2023)

11.10.4 BIOCAD Main Business Overview

11.10.5 BIOCAD Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Oncology Biosimilars Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)
- Table 2. Major Players of Monoclonal Antibody
- Table 3. Major Players of Hematopoietic Agents
- Table 4. Major Players of G-CSF
- Table 5. Major Players of Others
- Table 6. Oncology Biosimilars Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)
- Table 7. Global Oncology Biosimilars Market Size by Type (2018-2023) & (\$ Millions)
- Table 8. Global Oncology Biosimilars Market Size Market Share by Type (2018-2023)
- Table 9. Oncology Biosimilars Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)
- Table 10. Global Oncology Biosimilars Market Size by Application (2018-2023) & (\$ Millions)
- Table 11. Global Oncology Biosimilars Market Size Market Share by Application (2018-2023)
- Table 12. Global Oncology Biosimilars Revenue by Players (2018-2023) & (\$ Millions)
- Table 13. Global Oncology Biosimilars Revenue Market Share by Player (2018-2023)
- Table 14. Oncology Biosimilars Key Players Head office and Products Offered
- Table 15. Oncology Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
- Table 16. New Products and Potential Entrants
- Table 17. Mergers & Acquisitions, Expansion
- Table 18. Global Oncology Biosimilars Market Size by Regions 2018-2023 & (\$ Millions)
- Table 19. Global Oncology Biosimilars Market Size Market Share by Regions (2018-2023)
- Table 20. Global Oncology Biosimilars Revenue by Country/Region (2018-2023) & (\$ millions)
- Table 21. Global Oncology Biosimilars Revenue Market Share by Country/Region (2018-2023)
- Table 22. Americas Oncology Biosimilars Market Size by Country (2018-2023) & (\$ Millions)
- Table 23. Americas Oncology Biosimilars Market Size Market Share by Country (2018-2023)
- Table 24. Americas Oncology Biosimilars Market Size by Type (2018-2023) & (\$

Millions)

Table 25. Americas Oncology Biosimilars Market Size Market Share by Type (2018-2023)

Table 26. Americas Oncology Biosimilars Market Size by Application (2018-2023) & (\$ Millions)

Table 27. Americas Oncology Biosimilars Market Size Market Share by Application (2018-2023)

Table 28. APAC Oncology Biosimilars Market Size by Region (2018-2023) & (\$ Millions)

Table 29. APAC Oncology Biosimilars Market Size Market Share by Region (2018-2023)

Table 30. APAC Oncology Biosimilars Market Size by Type (2018-2023) & (\$ Millions)

Table 31. APAC Oncology Biosimilars Market Size Market Share by Type (2018-2023)

Table 32. APAC Oncology Biosimilars Market Size by Application (2018-2023) & (\$ Millions)

Table 33. APAC Oncology Biosimilars Market Size Market Share by Application (2018-2023)

Table 34. Europe Oncology Biosimilars Market Size by Country (2018-2023) & (\$ Millions)

Table 35. Europe Oncology Biosimilars Market Size Market Share by Country (2018-2023)

Table 36. Europe Oncology Biosimilars Market Size by Type (2018-2023) & (\$ Millions)

Table 37. Europe Oncology Biosimilars Market Size Market Share by Type (2018-2023)

Table 38. Europe Oncology Biosimilars Market Size by Application (2018-2023) & (\$ Millions)

Table 39. Europe Oncology Biosimilars Market Size Market Share by Application (2018-2023)

Table 40. Middle East & Africa Oncology Biosimilars Market Size by Region (2018-2023) & (\$ Millions)

Table 41. Middle East & Africa Oncology Biosimilars Market Size Market Share by Region (2018-2023)

Table 42. Middle East & Africa Oncology Biosimilars Market Size by Type (2018-2023) & (\$ Millions)

Table 43. Middle East & Africa Oncology Biosimilars Market Size Market Share by Type (2018-2023)

Table 44. Middle East & Africa Oncology Biosimilars Market Size by Application (2018-2023) & (\$ Millions)

Table 45. Middle East & Africa Oncology Biosimilars Market Size Market Share by Application (2018-2023)

Table 46. Key Market Drivers & Growth Opportunities of Oncology Biosimilars

Table 47. Key Market Challenges & Risks of Oncology Biosimilars

Table 48. Key Industry Trends of Oncology Biosimilars

Table 49. Global Oncology Biosimilars Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 50. Global Oncology Biosimilars Market Size Market Share Forecast by Regions (2024-2029)

Table 51. Global Oncology Biosimilars Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 52. Global Oncology Biosimilars Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 53. Celltrion Details, Company Type, Oncology Biosimilars Area Served and Its Competitors

Table 54. Celltrion Oncology Biosimilars Product Offered

Table 55. Celltrion Oncology Biosimilars Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 56. Celltrion Main Business

Table 57. Celltrion Latest Developments

Table 58. Biocon Details, Company Type, Oncology Biosimilars Area Served and Its Competitors

Table 59. Biocon Oncology Biosimilars Product Offered

Table 60. Biocon Main Business

Table 61. Biocon Oncology Biosimilars Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 62. Biocon Latest Developments

Table 63. Dr. Reddy's Laboratories Details, Company Type, Oncology Biosimilars Area Served and Its Competitors

Table 64. Dr. Reddy's Laboratories Oncology Biosimilars Product Offered

Table 65. Dr. Reddy's Laboratories Main Business

Table 66. Dr. Reddy's Laboratories Oncology Biosimilars Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 67. Dr. Reddy's Laboratories Latest Developments

Table 68. STADA Arzneimittel AG Details, Company Type, Oncology Biosimilars Area Served and Its Competitors

Table 69. STADA Arzneimittel AG Oncology Biosimilars Product Offered

Table 70. STADA Arzneimittel AG Main Business

Table 71. STADA Arzneimittel AG Oncology Biosimilars Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 72. STADA Arzneimittel AG Latest Developments

Table 73. Intas Pharmaceuticals Details, Company Type, Oncology Biosimilars Area

Served and Its Competitors

Table 74. Intas Pharmaceuticals Oncology Biosimilars Product Offered

Table 75. Intas Pharmaceuticals Main Business

Table 76. Intas Pharmaceuticals Oncology Biosimilars Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 77. Intas Pharmaceuticals Latest Developments

Table 78. Pfizer Details, Company Type, Oncology Biosimilars Area Served and Its Competitors

Table 79. Pfizer Oncology Biosimilars Product Offered

Table 80. Pfizer Main Business

Table 81. Pfizer Oncology Biosimilars Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 82. Pfizer Latest Developments

Table 83. Sandoz International Details, Company Type, Oncology Biosimilars Area Served and Its Competitors

Table 84. Sandoz International Oncology Biosimilars Product Offered

Table 85. Sandoz International Main Business

Table 86. Sandoz International Oncology Biosimilars Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 87. Sandoz International Latest Developments

Table 88. Teva Pharmaceutical Industries Ltd Details, Company Type, Oncology Biosimilars Area Served and Its Competitors

Table 89. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Offered

Table 90. Teva Pharmaceutical Industries Ltd Main Business

Table 91. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 92. Teva Pharmaceutical Industries Ltd Latest Developments

Table 93. Apotex Details, Company Type, Oncology Biosimilars Area Served and Its Competitors

Table 94. Apotex Oncology Biosimilars Product Offered

Table 95. Apotex Main Business

Table 96. Apotex Oncology Biosimilars Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 97. Apotex Latest Developments

Table 98. BIOCAD Details, Company Type, Oncology Biosimilars Area Served and Its Competitors

Table 99. BIOCAD Oncology Biosimilars Product Offered

Table 100. BIOCAD Main Business

Table 101. BIOCAD Oncology Biosimilars Revenue (\$ million), Gross Margin and

Market Share (2018-2023)

Table 102. BIOCAD Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Oncology Biosimilars Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Oncology Biosimilars Market Size Growth Rate 2018-2029 (\$ Millions)
- Figure 6. Oncology Biosimilars Sales by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Figure 7. Oncology Biosimilars Sales Market Share by Country/Region (2022)
- Figure 8. Oncology Biosimilars Sales Market Share by Country/Region (2018, 2022 & 2029)
- Figure 9. Global Oncology Biosimilars Market Size Market Share by Type in 2022
- Figure 10. Oncology Biosimilars in Retail Pharmacies
- Figure 11. Global Oncology Biosimilars Market: Retail Pharmacies (2018-2023) & (\$ Millions)
- Figure 12. Oncology Biosimilars in Hospital Pharmacy
- Figure 13. Global Oncology Biosimilars Market: Hospital Pharmacy (2018-2023) & (\$ Millions)
- Figure 14. Oncology Biosimilars in Online Pharmacy
- Figure 15. Global Oncology Biosimilars Market: Online Pharmacy (2018-2023) & (\$ Millions)
- Figure 16. Global Oncology Biosimilars Market Size Market Share by Application in 2022
- Figure 17. Global Oncology Biosimilars Revenue Market Share by Player in 2022
- Figure 18. Global Oncology Biosimilars Market Size Market Share by Regions (2018-2023)
- Figure 19. Americas Oncology Biosimilars Market Size 2018-2023 (\$ Millions)
- Figure 20. APAC Oncology Biosimilars Market Size 2018-2023 (\$ Millions)
- Figure 21. Europe Oncology Biosimilars Market Size 2018-2023 (\$ Millions)
- Figure 22. Middle East & Africa Oncology Biosimilars Market Size 2018-2023 (\$ Millions)
- Figure 23. Americas Oncology Biosimilars Value Market Share by Country in 2022
- Figure 24. United States Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)
- Figure 25. Canada Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)
- Figure 26. Mexico Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 27. Brazil Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 28. APAC Oncology Biosimilars Market Size Market Share by Region in 2022

Figure 29. APAC Oncology Biosimilars Market Size Market Share by Type in 2022

Figure 30. APAC Oncology Biosimilars Market Size Market Share by Application in 2022

Figure 31. China Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 32. Japan Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 33. Korea Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 34. Southeast Asia Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 35. India Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 36. Australia Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 37. Europe Oncology Biosimilars Market Size Market Share by Country in 2022

Figure 38. Europe Oncology Biosimilars Market Size Market Share by Type (2018-2023)

Figure 39. Europe Oncology Biosimilars Market Size Market Share by Application (2018-2023)

Figure 40. Germany Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 41. France Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 42. UK Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 43. Italy Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 44. Russia Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 45. Middle East & Africa Oncology Biosimilars Market Size Market Share by Region (2018-2023)

Figure 46. Middle East & Africa Oncology Biosimilars Market Size Market Share by Type (2018-2023)

Figure 47. Middle East & Africa Oncology Biosimilars Market Size Market Share by Application (2018-2023)

Figure 48. Egypt Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 49. South Africa Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 50. Israel Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 51. Turkey Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 52. GCC Country Oncology Biosimilars Market Size Growth 2018-2023 (\$ Millions)

Figure 53. Americas Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 54. APAC Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 55. Europe Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 56. Middle East & Africa Oncology Biosimilars Market Size 2024-2029 (\$

Millions)

Figure 57. United States Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 58. Canada Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 59. Mexico Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 60. Brazil Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 61. China Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 62. Japan Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 63. Korea Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 64. Southeast Asia Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 65. India Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 66. Australia Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 67. Germany Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 68. France Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 69. UK Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 70. Italy Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 71. Russia Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 72. Spain Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 73. Egypt Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 74. South Africa Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 75. Israel Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 76. Turkey Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 77. GCC Countries Oncology Biosimilars Market Size 2024-2029 (\$ Millions)

Figure 78. Global Oncology Biosimilars Market Size Market Share Forecast by Type (2024-2029)

Figure 79. Global Oncology Biosimilars Market Size Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Oncology Biosimilars Market Growth (Status and Outlook) 2023-2029

Product link: <https://marketpublishers.com/r/GA935E0DE7C5EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA935E0DE7C5EN.html>